| CAS NO: | 68377-92-4 |
| 包装 | 价格(元) |
| 10 mM * 1 mL in DMSO | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 生物活性 | Arotinolol is a nonselectiveα/β-adrenergic receptorblocker and a vasodilating β-blocker[1]. Arotinolol also shows potency for inhibiting the binding of the radioligand125I-ICYP to5HT1B-serotonergic receptorsites[2]. Arotinolol is anantihypertensive agentfor the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases[1]. | ||||||||||||||||
| IC50& Target[2] |
| ||||||||||||||||
| 体外研究 (In Vitro) | Arotinolol shows its selectivity of β-adrenergic receptors, the result of Arotinolol for β1 and β2 adrenoceptors in125I-ICYP binding to rat cerebral cortical membranes with pKivalue of 9.74 and 9.26 respectively. The selectively of β1 and β2 is equal[2].Arotinolol shows its potency for inhibiting the binding of the same radioligand to 5HT1B-serotonergic receptor site, Arotinolol displaces125I-ICYP binding to 5HT1B-receptors with the pKivalues of 7.97 and 8.16 resepectively for β1 and β2 adrenergic receptors[2]. | ||||||||||||||||
| 体内研究 (In Vivo) | Arotinolol (oral gavage; 200 mg/kg; 8 weeks) can significantly decrease central arterial pressure (CAP) and pulse wave velocity (PWV), in addition, it reduces aortic collagen depositions and finally improves arterial stiffness in SHR mouse[1].
| ||||||||||||||||
| Clinical Trial | |||||||||||||||||
| 分子量 | 371.54 | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| Formula | C15H21N3O2S3 | ||||||||||||||||
| CAS 号 | 68377-92-4 | ||||||||||||||||
| 中文名称 | 阿罗洛尔 | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 |
| ||||||||||||||||
| 溶解性数据 | In Vitro: DMSO : 125 mg/mL(336.44 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
